Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach

Clinician-trialist rounds: 6. Testing for blindness at the end of your trial is a mug's game

(2011) David L Sackett   Clinical Trials

CONSORT 2010 changes and testing blindness in RCTs

(2010) Kenneth F Schulz et al.   LANCET

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

(2010) Derick T Wade et al.   Multiple Sclerosis Journal

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Stop using the Ashworth Scale for the assessment of spasticity

(2009) J F M Fleuren et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

(2008) John T. Farrar et al.   CLINICAL THERAPEUTICS

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

(2008) Lesley Wood et al.   BMJ-British Medical Journal